Table 3.
Clinical characteristics of prostate cancers in carries of variant alleles in NBN
| 657del5 mutation (n=74) | p-value | 657del5 and E185Q GG genotype (n=50) | p-value | 657del5 and E185Q non-GG genotype (n=24) | p-value | Neither genotypea) (n=2,958) | |
|---|---|---|---|---|---|---|---|
| Age of diagnosis (yr) | |||||||
| Mean | 67.0 | 0.505 | 67.0 | 0.586 | 67.0 | 0.697 | 67.8 |
| PSA level at diagnosis (ng/mL) | |||||||
| Median | 11.7 | 0.592 | 13.4 | 0.237 | 8.6 | 0.532 | 11.8 |
| ≤ 4.0 | 1/44 (2.3) | 0.724 | 1/27 (3.7) | 1.000 | 0/17 (0.0) | 1.000 | 86/1,652 (5.2) |
| 4.1-10 | 17/44 (38.6) | 1.000 | 6/27 (22.2) | 0.077 | 11/17 (64.7) | 0.044 | 647/1,652 (39.2) |
| 10.1-20.0 | 11/44 (25.0) | 1.000 | 9/27 (33.3) | 0.367 | 2/17 (11.8) | 0.271 | 407/1,652 (24.6) |
| > 20.0 | 15/44 (34.1) | 0.742 | 11/27 (40.7) | 0.297 | 4/17 (23.5) | 0.607 | 512/1,652 (30.1) |
| Gleason score | |||||||
| < 7 | 25/54 (47.2) | 0.522 | 17/36 (47.2) | 0.618 | 8/18 (44.4) | 0.638 | 1,011/1,957 (51.7) |
| 7 | 15/54 (28.3) | 0.892 | 8/36 (22.2) | 0.460 | 7/18 (38.9) | 0.438 | 579/1,957 (29.6) |
| > 7 | 14/54 (24.5) | 0.250 | 11/36 (30.6) | 0.085 | 3/18 (16.7) | 1.000 | 367/1,957 (18.7) |
| Stage | |||||||
| T1 | 14/49 (28.6) | 0.755 | 7/32 (21.9) | 0.256 | 7/17 (41.2) | 0.437 | 467/1,467 (31.8) |
| T2 | 16/49 (32.7) | 0.186 | 11/32 (34.4) | 0.370 | 5/17 (29.4) | 0.328 | 632/1,467 (43.1) |
| T3 | 8/49 (16.3) | 0.852 | 5/32 (15.6) | 0.820 | 3/17 (17.6) | 1.000 | 272/1,467 (18.5) |
| T4 | 11/49 (22.4) | 0.0004 | 9/32 (28.1) | 0.0002 | 2/17 (11.8) | 0.311 | 96/1,467 (6.5) |
| T3 or T4 | 19/49 (38.8) | 0.044 | 14/32 (43.7) | 0.023 | 5/17 (29.4) | 0.778 | 368/1,467 (25.1) |
Values are presented as number (%) unless otherwise indicated.
a)
p-values are calculated with respect to carriers of neither genotype (657del5 negative and E185Q GG genotype negative cases) as reference group.